erlotinib hydrochloride has been researched along with tacrolimus in 1 studies
Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (tacrolimus) | Trials (tacrolimus) | Recent Studies (post-2010) (tacrolimus) |
---|---|---|---|---|---|
4,353 | 786 | 3,033 | 17,757 | 2,319 | 6,661 |
Protein | Taxonomy | erlotinib hydrochloride (IC50) | tacrolimus (IC50) |
---|---|---|---|
Bile salt export pump | Homo sapiens (human) | 7.18 | |
Cytochrome P450 3A4 | Homo sapiens (human) | 0.58 | |
Cytochrome P450 3A5 | Homo sapiens (human) | 0.385 | |
Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0021 | |
Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.2547 | |
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform | Homo sapiens (human) | 0.0148 | |
Splicing factor 3B subunit 3 | Homo sapiens (human) | 0.0123 | |
Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 3.3 | |
Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 3.7 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Basti, S; Benson, A; Lacouture, ME; Patel, J | 1 |
1 other study(ies) available for erlotinib hydrochloride and tacrolimus
Article | Year |
---|---|
The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.
Topics: Algorithms; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Dermatology; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Eye Diseases; Female; Humans; Interprofessional Relations; Lung Neoplasms; Medical Oncology; Middle Aged; Ophthalmology; Quinazolines; Referral and Consultation; Skin Diseases; Tacrolimus | 2006 |